Last updated: September 21, 2026
Rolapitant hydrochloride, marketed as Varubi by Tesaro and later GSK, was a commercial underperformer in the neurokinin-1 receptor antagonist market. The FDA approved oral Varubi in 2015 for prevention of delayed chemotherapy-induced nausea and vomiting. An intravenous formulation was approved in 2017 but withdrawn after postmarketing reports of anaphylaxis and other hypersensitivity reactions. GSK later discontinued U.S. commercialization.
The product generated limited revenue relative to Tesaro's oncology franchise. Its market position weakened because it competed against established aprepitant products, fosaprepitant, and the fixed-dose netupitant-palonosetron combination while carrying a narrow antiemetic indication and limited prescribing differentiation.
What is rolapitant hydrochloride and how does it work?
Rolapitant hydrochloride is a selective neurokinin-1, or NK1, receptor antagonist. The oral product was supplied as 90 mg tablets and used with a serotonin 5-HT3 receptor antagonist and dexamethasone for patients receiving moderately or highly emetogenic cancer chemotherapy.
Rolapitant's principal pharmacologic differentiator was its long terminal half-life, approximately seven days. This supported single-dose administration before chemotherapy and prolonged blockade of substance P signaling during the delayed phase of chemotherapy-induced nausea and vomiting. The product also did not inhibit or induce CYP3A4, an interaction advantage over aprepitant-based regimens in some clinical settings.[1]
FDA regulatory milestones
| Event |
Date |
Commercial significance |
| FDA approval of oral Varubi tablets |
September 1, 2015 |
Authorized U.S. launch |
| FDA approval of intravenous rolapitant emulsion |
2017 |
Expanded product into institutional and infusion-center use |
| Reports of serious hypersensitivity reactions with IV formulation |
2017-2018 |
Triggered regulatory and commercial disruption |
| Voluntary U.S. withdrawal of IV rolapitant |
2018 |
Removed the second dosage form |
| Tesaro acquired by GSK |
March 2019 |
Transferred product ownership to GSK |
| U.S. commercial discontinuation |
By 2020 |
Ended active branded commercialization |
FDA approval was limited to prevention of acute and delayed nausea and vomiting associated with chemotherapy. Rolapitant was not approved as a broad antiemetic for postoperative nausea, radiotherapy-induced nausea, or general gastrointestinal indications.[1]
How did rolapitant compare with competing antiemetics?
Rolapitant entered a crowded NK1 antagonist market. Its closest competitors were Merck's Emend franchise, including aprepitant and injectable fosaprepitant, and Helsinn's Akynzeo, a fixed-dose combination of netupitant and palonosetron.
| Product |
Active ingredient |
Main commercial advantage |
Main competitive constraint |
| Varubi |
Rolapitant |
Long duration; limited CYP3A4 interaction profile |
Limited market access and later discontinuation |
| Emend |
Aprepitant |
Established clinical adoption and broad formulation history |
CYP3A4 interaction management |
| Fosaprepitant |
Prodrug of aprepitant |
Intravenous administration and hospital familiarity |
Infusion use and interaction considerations |
| Akynzeo |
Netupitant/palonosetron |
Two-pathway fixed-dose product |
Higher branded cost and formulary competition |
| Generic aprepitant |
Aprepitant |
Low acquisition cost |
Lower differentiation and interaction burden |
Rolapitant's pharmacology was commercially attractive, but the product did not establish a durable formulary position. Oncology practices often use guideline-based antiemetic protocols that favor familiar branded combinations, hospital contracts, and generic aprepitant alternatives. A pharmacokinetic benefit alone was insufficient to offset those purchasing dynamics.
What caused the commercial failure of Varubi?
The key commercial failure was not a single patent event. It was the combination of weak market uptake, formulation safety problems, restricted indication breadth, and competitive pricing pressure.
IV formulation withdrawal
The intravenous formulation was associated with serious hypersensitivity reactions, including anaphylaxis. Tesaro withdrew the product from the U.S. market in 2018 after discussions with the FDA. That decision removed a potentially important channel into hospitals and infusion centers, where injectable antiemetics are commonly incorporated into chemotherapy protocols.[2]
The withdrawal also reduced confidence in the broader brand. Although the oral formulation was not subject to the same withdrawal, the product lost a meaningful part of its commercial strategy.
Limited prescribing differentiation
Rolapitant offered long duration and a lower CYP3A4 interaction burden than aprepitant. Those advantages did not translate into broad adoption because:
- clinicians already had multiple NK1 antagonist options;
- many patients received antiemetic protocols controlled by institutional pathways;
- generic or contract-priced aprepitant products created strong budget pressure;
- the product required combination use with a 5-HT3 antagonist and dexamethasone;
- the FDA label did not create a broad, high-volume outpatient indication.
Commercial execution
Tesaro's primary growth asset was Zejula, its PARP inhibitor for ovarian cancer. Commercial resources and investor attention were directed toward Zejula rather than Varubi. After GSK acquired Tesaro, the strategic value of maintaining a low-revenue antiemetic brand was limited.
GSK's subsequent discontinuation of Varubi reflected portfolio rationalization. The product did not provide a material contribution to GSK's larger oncology business.
What were Varubi's sales and financial trajectory?
Varubi was a minor contributor to Tesaro's revenue throughout its commercial life. Public company disclosures separated or discussed Varubi product revenue alongside the much larger Zejula franchise.
| Period |
Financial direction |
Interpretation |
| 2015-2016 |
Initial launch and limited uptake |
Market entry did not produce rapid scale |
| 2017 |
Revenue remained modest |
IV approval expanded the opportunity but did not transform the franchise |
| 2018 |
Product disruption after IV withdrawal |
Safety event impaired institutional adoption |
| 2019 |
Ownership transferred to GSK |
Product became non-core within a larger oncology portfolio |
| 2020 onward |
U.S. commercialization discontinued |
No meaningful branded growth trajectory remained |
Tesaro's filings show the central financial pattern: Zejula became the company's dominant revenue-generating product, while Varubi remained comparatively small. The antiemetic was not positioned to offset the substantial research, manufacturing, sales, and distribution costs associated with a branded oncology launch.[3]
The product's economics were also constrained by its treatment setting. Chemotherapy-induced nausea and vomiting is clinically important but generally produces lower revenue per treated patient than chronic oncology maintenance therapies. Anti-emetic treatment is frequently subject to hospital formulary review and payer substitution, reducing pricing power.
When did rolapitant lose exclusivity, and what is the generic entry risk?
The practical loss of exclusivity occurred through commercial withdrawal rather than a visible generic launch. The oral product was discontinued before a large generic market developed, and the IV product had already been withdrawn.
The U.S. generic risk profile is therefore unusual:
- There was no major branded product left to defend after commercialization ended.
- Market demand was limited by the discontinuation of the reference product.
- Generic manufacturers had little incentive to invest in an ANDA for a product with weak branded sales and several established alternatives.
- Institutional customers could substitute aprepitant-based products or other NK1 antagonists without waiting for a rolapitant generic.
Paragraph IV challenges and ANDA activity
No prominent public Paragraph IV litigation involving a commercially significant rolapitant hydrochloride ANDA is identified in the cited FDA and company record. No approved generic has become a visible U.S. competitor to Varubi.
That does not mean all patent barriers were immaterial. A generic applicant would have evaluated composition, formulation, polymorph, dosing, and method-of-use claims. The commercial value of that challenge, however, was limited because product discontinuation reduced the addressable market.
What patents protected rolapitant hydrochloride?
Rolapitant was protected by a patent estate covering the active pharmaceutical compound and related pharmaceutical use and formulation concepts. The relevant categories included:
- composition-of-matter claims directed to rolapitant or related NK1 antagonist structures;
- pharmaceutical compositions containing rolapitant hydrochloride;
- oral dosing for prevention of chemotherapy-induced nausea and vomiting;
- use with 5-HT3 antagonists and corticosteroids;
- injectable or emulsion formulations;
- manufacturing and formulation processes.
The commercial importance of these patents declined after the IV withdrawal and the later discontinuation of the oral product. Method-of-use patents were particularly vulnerable because generic applicants could pursue a section viii labeling strategy, where permitted, or rely on non-infringing labeling if remaining claims were narrow.
Orange Book status
Varubi was an FDA-approved small-molecule drug, so its U.S. patent and exclusivity profile was evaluated through the Orange Book framework rather than the biologic Purple Book system. It was not a biologic and did not create biosimilar substitution risk.
The relevant regulatory distinction is important:
- generic applicants would file abbreviated new drug applications, or ANDAs;
- biosimilar applicants would not use the 351(k) pathway;
- patent disputes would arise under the Hatch-Waxman framework;
- patent listings would depend on whether claims covered the approved drug, formulation, or approved use.
What formulation and manufacturing barriers affected rolapitant?
The oral tablet had relatively conventional pharmaceutical manufacturing characteristics. Its main technical protection came from the active molecule, formulation composition, and dosage regimen rather than from an unusually complex delivery platform.
The IV product was more difficult commercially and operationally. Injectable emulsion products require tighter control of particle size, sterility, excipient compatibility, container closure, and infusion safety. The hypersensitivity signal made those technical and clinical risks more important. Once the IV formulation was withdrawn, the injectable manufacturing barrier ceased to provide commercial value.
Manufacturing did not create a durable moat. Established pharmaceutical manufacturers could potentially reproduce the oral dosage form if patent and regulatory requirements were satisfied. The larger barrier was demand: clinicians had little reason to switch from familiar alternatives after the Varubi brand disappeared.
Which companies challenged or competed with rolapitant?
No company became a major litigation challenger to Varubi. Competition was primarily commercial and therapeutic.
Established pharmaceutical competitors
- Merck marketed Emend and related aprepitant products.
- Helsinn marketed Akynzeo.
- Generic manufacturers supplied aprepitant after relevant market exclusivities expired.
- Hospital suppliers and specialty distributors competed through contracts, formulary placement, and injectable antiemetic bundles.
The competitive threat came from substitution rather than direct patent litigation. A pharmacy or oncology practice could select another NK1 antagonist without adopting a rolapitant-specific protocol.
What is the current commercial outlook for rolapitant hydrochloride?
The current U.S. outlook is inactive. Varubi is no longer a growth product, and there is no meaningful branded revenue trajectory following discontinuation.
Future commercial opportunities would require a new sponsor to establish a regulatory and commercial case for rolapitant, potentially through:
- reintroduction of oral tablets;
- licensing into markets where the product remains approved or available;
- a new combination product;
- a reformulated injectable product with a different safety profile;
- a clinical positioning strategy focused on drug-interaction reduction.
Those opportunities face substantial barriers. Existing NK1 antagonists are entrenched, generic aprepitant is available in many markets, and a relaunch would require new manufacturing, distribution, medical-affairs, and reimbursement investment.
How strong is the rolapitant patent estate compared with its market value?
The patent estate had greater theoretical value than the commercial market ultimately supported. Composition and use claims could delay direct generic competition, but exclusivity does not create demand. Once sales remained low and the IV formulation was withdrawn, the economic value of enforcing the estate fell.
Rolapitant is therefore best classified as a discontinued branded small molecule with limited residual patent and licensing value. It is not a current biosimilar target, a major generic litigation asset, or a meaningful contributor to GSK's revenue base.
Key Takeaways
- Rolapitant hydrochloride was approved by the FDA in 2015 as oral Varubi for chemotherapy-induced nausea and vomiting.
- Its main clinical differentiators were long duration of action and limited CYP3A4 interaction.
- The IV formulation was withdrawn after serious hypersensitivity reactions.
- Tesaro's commercial focus remained on Zejula, while Varubi generated only modest revenue.
- GSK acquired Tesaro in 2019 and later discontinued U.S. Varubi commercialization.
- Competition from aprepitant, fosaprepitant, Akynzeo, and generic antiemetics limited pricing power.
- No major public Paragraph IV litigation or commercial generic launch reshaped the market.
- The product's effective commercial loss of exclusivity resulted from discontinuation and weak demand rather than a major generic-entry event.
- Residual patent value is limited by the absence of an active U.S. branded market.
FAQs
Is rolapitant hydrochloride still marketed in the United States?
No. U.S. commercialization of Varubi was discontinued after Tesaro was acquired by GSK.
Is rolapitant hydrochloride a biologic or biosimilar product?
No. Rolapitant is a chemically synthesized small molecule and would be subject to the ANDA pathway for generic competition.
What drug replaced Varubi in clinical practice?
There was no single replacement. Clinicians generally used aprepitant, fosaprepitant, netupitant-palonosetron, and other guideline-supported antiemetic regimens.
Did the Varubi IV withdrawal affect the oral tablets?
The IV withdrawal was driven by hypersensitivity concerns associated with the injectable product. The later commercial discontinuation of the oral product reflected broader portfolio and market decisions.
Does rolapitant have significant licensing value today?
Its licensing value is limited. A new license would require a sponsor to overcome established competition, limited demand, discontinued U.S. commercialization, and the cost of rebuilding regulatory and commercial infrastructure.
References
- U.S. Food and Drug Administration. (2015). Varubi (rolapitant hydrochloride) tablets prescribing information.
- U.S. Food and Drug Administration. (2017-2018). Safety communications and regulatory information concerning intravenous rolapitant.
- Tesaro, Inc. (2016-2018). Annual reports and Form 10-K filings.
- GlaxoSmithKline plc. (2019-2020). Annual reports.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
